Sperandeo Maria P, Paladino Simona, Maiuri Luigi, Maroupulos George D, Zurzolo Chiara, Taglialatela Maurizio, Andria Generoso, Sebastio Gianfranco
Department of Pediatrics, Federico II University, Naples, Italy.
Eur J Hum Genet. 2005 May;13(5):628-34. doi: 10.1038/sj.ejhg.5201376.
Lysinuric protein intolerance (LPI) is an inherited aminoaciduria caused by defective cationic amino acid (CAA) transport at the basolateral membrane of epithelial cells in the intestine and kidney. The SLC7A7 gene, mutated in LPI, encodes the y(+)LAT-1 protein, which is the light subunit of the heterodimeric CAA transporter in which 4F2hc is the heavy chain subunit. Co-expression of 4F2hc and y(+)LAT-1 induces the y(+)L activity. This activity is also exerted by another complex composed of 4F2hc and y(+)LAT-2, the latter encoded by the SLC7A6 gene and more ubiquitously expressed than SLC7A7. On the basis of both the pattern of expression and the transport activity, y(+)LAT-2 might compensate for CAA transport when y(+)LAT-1 is defective. By expression in Xenopus laevis oocytes and mammalian cells, we functionally analysed two SLC7A7 mutants, E36del and F152L, respectively, the former displaying a partial dominant-negative effect. The results of the present study provide further insight into the molecular pathogenesis of LPI: a putative multiheteromeric structure of both [4F2hc/y(+)LAT-1] and [4F2hc/y(+)LAT-2], and the interference between y(+)LAT-1 and y(+)LAT-2 proteins. This interference can explain why the compensatory mechanism, that is, an increased expression of SLC7A6 as seen in lymphoblasts from LPI patients, may not be sufficient to restore the y(+)L system activity.
赖氨酸尿性蛋白不耐受症(LPI)是一种遗传性氨基酸尿症,由肠道和肾脏上皮细胞基底外侧膜上的阳离子氨基酸(CAA)转运缺陷引起。LPI中发生突变的SLC7A7基因编码y(+)LAT-1蛋白,它是异二聚体CAA转运体的轻链亚基,其中4F2hc是重链亚基。4F2hc和y(+)LAT-1的共表达诱导y(+)L活性。这种活性也由另一种由4F2hc和y(+)LAT-2组成的复合物发挥,后者由SLC7A6基因编码,且比SLC7A7表达更广泛。基于表达模式和转运活性,当y(+)LAT-1有缺陷时,y(+)LAT-2可能补偿CAA转运。通过在非洲爪蟾卵母细胞和哺乳动物细胞中的表达,我们分别对两个SLC7A7突变体E36del和F152L进行了功能分析,前者表现出部分显性负效应。本研究结果为LPI的分子发病机制提供了进一步的见解:[4F2hc/y(+)LAT-1]和[4F2hc/y(+)LAT-2]的假定多聚体结构,以及y(+)LAT-1和y(+)LAT-2蛋白之间的干扰。这种干扰可以解释为什么补偿机制,即在LPI患者的淋巴母细胞中所见的SLC7A6表达增加,可能不足以恢复y(+)L系统活性。